Eosinophilic Esophagitis Pathophysiology and Burdens

Program Description

This Phone-a-Friend™ activity module features a gastroenterologist and an allergist discussing the burdens of EoE, as well as the inflammatory pathway that drives the disease process and common comorbidities found in patients with EoE.  

Target Audience

This activity is designed to address identified knowledge and practice gaps among allergists/clinical immunologists, gastroenterologists, and other specialist clinicians involved in the management of adult and pediatric patients with eosinophilic esophagitis (EoE).

Educational Objective 

After completing this activity, the participant should be better able to:

• Explain key pathophysiologic processes in EoE development, including the rationale for new therapeutic options  

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC CREDIT

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Carla M. Davis, MD: Consulting Fees: Genentech, Inc.; Contracted Research: Allergenis, Inc., DBV Technologies, Food Allergy Research & Education, Regeneron Pharmaceuticals, Inc., Sanofi, Takeda Pharmaceutical Company Limited

Evan S. Dellon, MD, MPH: Consulting Fees: Abbott Laboratories, AbbVie Inc., Adare Pharma Solutions, Inc./Ellodi Pharmaceuticals, Aimmune Therapeutics, Akeso Biopharma Co., Ltd, Alfasigma USA, Inc., ALK-Abelló A/S, Allakos Inc., Amgen Inc., Apollo Endosurgery, Aqilion AB, Arena Pharmaceuticals, Inc./Pfizer Inc., ASLAN Pharmaceuticals, AstraZeneca, Avir, Biorasi LLC, Bryn Pharma, Calypso Biotech SA, Celgene Corporation/Receptos Inc./Bristol Myers Squibb, Celldex Therapeutics, Inc., Eli Lilly and Company, EsoCap AG, Eupraxia Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Ferring Pharmaceuticals, Inc., GSK, Gossamer Bio, Holoclara Inc., Invea Therapeutics. Inc., Knightpoint, Landos Biopharma, Inc., LucidDx Labs Inc., Morphic Therapeutic, Nexstone Immunology/Uniquity Bio, Nutricia, Parexel Informatics/Calyx Inc., Phathom Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Revolo Biotherapeutics, Robarts Clinical Trials/Alimentiv, Inc., Salix Pharmaceuticals, Sanofi, Shire plc/Takeda Pharmaceutical Company, Target RWE, Upstream Bio, Inc.; Contracted Research: Adare Pharma Solutions, Inc./Ellodi Pharmaceuticals, Inc., Allakkos Inc., Arena Pharmaceuticals, Inc./Pfizer Inc., AstraZeneca, Eupraxia Pharmaceuticals, Inc. Ferring Pharmaceuticals, Inc., GSK, Meritage Pharma, Inc., Miraca Life Sciences Inc., Nutricia, Celgene Corporation/Receptos Inc./Bristol Myers Squibb, Regeneron Pharmaceuticals, Inc., Revolo Biotherapeutics, Shire plc/Takeda Pharmaceutical Company

The Integritas planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.